Lipoprotein and Apolipoproteins With Metabolic Liver Diseases

NCT03220971 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 440

Last updated 2018-04-19

No results posted yet for this study

Summary

Theranostic translation applications against viral, metabolic liver diseases and hepatic oncogenesis: lipoprotein and apolipoproteins at a crossroad

Conditions

  • Disorders of Lipoprotein Metabolism and Other Lipidaemias

Interventions

OTHER

lipoprotein and apolipoproteins

To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases

Sponsors & Collaborators

  • Chun-Hsiang Wang

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-20
Primary Completion
2019-10-31
Completion
2019-10-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03220971 on ClinicalTrials.gov